Please enable JavaScript.

Coggle requires JavaScript to display documents.

Psilocybin as a Third-Line Therapy for Major Depressive Disorder…

- - - - with insurance: $80 per 60 day supply
      - without insurance: $341.33 per 60 day supply
      - assistance program (y)
      - Generic: $15.23 per month
  - - - With insurance: $130 per 60 day supply
      - without insurance: $464.51 per 60 day supply
      - assistance program (y)
  - - - without insurance: $880 per 2 sprays in one month
      - with insurance: $10 per spray dependent on coverage and eligibility
      - Study: Long-term value for money is subject to be about $198,000 per QALY, which exceeds the higher end of the range between $50,000 and $150,000 in the primary base case analysis. Exceeds higher end of the range, deemed low value
- - - - TRD: $3,743; MDD: $304
        
        Cormorbities associated with TRD additional costs
        
        diabetes
        
        heart disease
        
        stroke
    - - TRD: $8,659; MDD: $4,084
    - - TRD: $10,746 ; MDD: $3,476
    - - TRD: $12,092; MDD: $6,077
- - - - Required personnel
      - long treatment time
      - possible hospital stay
      - administration needs
    - - Assisted Therapy
        
        integration
        
        psilocybin session
        
        preparation
- - - - Compared to MDD, TRD patients are expected to occur between 1-2 times the healthcare costs
        
        Expected annual medical cost for a single TRD patient estimated as high as $16,590 in the 12 months receiving first antidepressant.
- - - - Total Revenue
      - total shares
      - total sales
    - - total sales
      - total revenue
      - total shares